Genmab's petosemtamab plus pembrolizumab halves risk of death in Phase 3 head and neck cancer trial
At the first interim analysis of LiGeR-HN1 the overall survival hazard ratio was 0.50; medians and full data were not disclosed.

Google cites gains in coding, agents and vulnerability work; broader access comes later, with introductory pricing of $2/$10 per million tokens.
At the first interim analysis of LiGeR-HN1 the overall survival hazard ratio was 0.50; medians and full data were not disclosed.

The change aims to curb benchmark contamination and adds FrontierCode 2.0; private tasks cannot be reviewed externally.
API pricing is $1 input and $5 output per million tokens; it is in ChatGPT Work and Codex for paid plans.
It has 104 billion active parameters and is live in Kimi apps and API; full open weights are promised by November 4.
Business Insider reports early talks after unsolicited offers; Cognition has not commented publicly.
New variants within a defined feature space could be added after approval without new trials; comments are due November 27.
In the 599-patient TALAPRO-3 trial the combination cut the risk of radiographic progression or death by 52% versus enzalutamide alone.
The 5,000-square-foot plant builds boards without line changeovers; speed and price-parity claims versus Shenzhen are the company's.

The repository holds about 43.1 million lines of Lean and flags 34 deviations from published arguments; independent review is pending.
It is a research preview for trusted testers, with rollout planned to AI Ultra subscribers and early API partners.
Several results are partial, bounded or counterexamples rather than full solutions, and none had been peer reviewed by October 24.